Eisai, Inc.
NBG, Global Medical Affairs
Harald J. Hampel, M.D., Ph.D., M.Sc., M.A., serves as Vice President and Chief Medical Officer (CMO) of the Neurology Business Group at Eisai Inc. and as a member of the company’s Executive Committee for the Americas. As CMO, Dr. Hampel is responsible for leading Eisai’s global medical affairs strategy and providing medical expertise in neurology with the aim of developing targeted solutions to prevent and treat neurological conditions.
With more than 25 years of experience conducting clinical trials in Alzheimer’s disease (AD) and related neurodegenerative diseases, Dr. Hampel provides executive direction and medical guidance in the planning and implementation of Eisai’s global therapeutic pipeline which includes AD, other dementia, epilepsy and sleep/wake disorders. He is also responsible for developing the global neurology medical affairs strategies for the company’s commercial products, pipeline assets and late-stage compounds approaching the commercialization stage.
Presenter of 1 Presentation
PRE-RECORDED: AMYLOID-Β PATHWAY ACROSS TIME AND SPACE IN ALZHEIMER’S DISEASE
Session Name
Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
04:15 PM - 06:15 PM
Room
ONSITE: 112
Lecture Time
05:45 PM - 06:00 PM
Abstract
Abstract Body
Amyloid-β (Aβ) as a hallmark of Alzheimer’s disease (AD) pathology and an early component in Alzheimer’s pathophysiology1 had led to the ongoing effort of therapeutic development that targets various species of Aβ. Despite decades of research, however, it is not yet clear what exact part of Aβ pathway — and when and where — confers detrimental effects to brain function and during which stages of the disease. For a structurally and functionally dynamic biochemical pathway, such as the Aβ cycle, the thorough understanding of epoch (temporal) and loci (spatial) of toxic effects of Aβ species will enrich our understanding of the AD pathophysiologic continuum and may provide further insights into therapeutic development. Here, a review of the existing literature of clinical and experimental studies will discuss various components of the Aβ pathway and their biological activities at molecular, cellular, and systematic loci across disease stages and time scale. Understanding Aβ dynamics in space and time may help identify new targets and guide drug development.1. Hampel H, Hardy J, Blennow K, et al. The Amyloid-β Pathway in Alzheimer's Disease [published online ahead of print, 2021 Aug 30]. Mol Psychiatry. 2021;10.1038/s41380-021-01249-0.